Worldwide, big pharma may be retrenching, but it continues to invest in China. Because China’s drug market is young and growing, the country represents opportunity for these industry veterans, an opportunity that is made more attractive by their difficulties elsewhere. It’s not surprising, therefore, that several big pharmas have expressed their intention to enlarge their presence in China. Novartis, Novo Nordisk, GlaxoSmithKline, Bayer Schering and Bristol-Myers Squibb have each been in China biopharma news in recent days. More details...

Stock Symbols: (NYSE: NVS) (NYSE: NVO) (NYSE: GSK) (NYSE: BMY)